News

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell ...
Targeted Oncology2h
Intratumoral BO-112 Plus Pembrolizumab Shows Promise in Anti–PD-1–Resistant Melanoma
A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...
The Manila Times3h
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics, Inc. (the 'Company” or 'Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device ...
Melanoma Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...
From larger chromosomes to bigger intenstines, the reasons why women outlive men
Research indicates women generally outlive men due to biological advantages. Genetics, hormones, and anatomical differences ...
Hosted on MSN19h
Common fungal molecule can prime lung immune cells for damaging overreaction to infection signals
Unlike the adaptive immune system, which learns to recognize specific viruses ... and observed the same heightened ...
eLife1d
Study reveals negative consequences of trained immunity in the lungs
A compound found in fungal cell walls can reprogram immune cells in the lungs, potentially worsening inflammation during infections.
The hidden physical powers that help women outlive men
Despite more complex reproductive organs and fewer resources, female bodies are built to get through hardship and disease, ...
AHA/ASA Journals21h
Cardiac Xenotransplantation: Current State and Future Directions
The increasing demand for donor hearts presents both a critical challenge and a significant opportunity for innovation in ...
Moleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...